Claret Capital Partners has raised €575m for its latest European growth-debt strategy, exceeding its original €500m target as companies continue to use private credit alongside conventional venture capital.
The London-based investment manager has closed Claret European Growth Capital Fund IV with €440m of commitments, accompanied by €135m of affiliated discretionary mandates.
Approximately 32% of the capital has already been deployed across 27 businesses in technology, life sciences, and impact sectors.
The fundraising takes total capital raised by Claret since inception to €1.3bn. The manager said it has deployed more than €1.5bn across more than 210 companies when recycled capital across successive fund generations is included.
The latest vehicle has already backed companies including B2B payments platform Billie, clinical-stage pharmaceutical groups Cinclus Pharma and Inventiva, commercial property software provider PRODA, medtech business SIS Medical, sales-intelligence platform Surfe, and energy-flexibility company VIOTAS.
Growth debt occupies a different place in a company’s capital structure from conventional venture equity.
Instead of selling an additional ownership stake, a business borrows capital that must be repaid over an agreed period, normally alongside interest and other negotiated protections.
The structure can appeal to companies with strong revenue growth or access to future financing whose existing shareholders want to limit further dilution.
It can also finance acquisitions, international expansion, product development, or a longer runway before the next equity round.
Debt introduces fixed financial obligations, however. A company that misses growth targets still has to service its borrowing, making the product better suited to businesses with a degree of financial predictability than very early-stage ventures with uncertain revenue.
The €575m close indicates continued institutional demand for financing models beyond conventional equity after several years of changing venture-market conditions.
During the period of exceptionally cheap capital, technology companies could raise successive equity rounds at rapidly increasing valuations.
As financing conditions tightened, founders and investors became more sensitive to dilution and to the risk of completing new rounds at valuations below previous financings.
Growth debt can provide another source of capital in some circumstances, although it does not remove the requirement for a company eventually to produce sufficient cash or raise further funding to repay lenders.
For investors, the asset class provides exposure to growth companies through contracted debt returns rather than depending entirely on equity appreciation and an eventual sale or flotation.
That can offer a different risk-and-return profile at a time when private-company exits have taken longer and public markets have remained selective about new listings.
Claret’s fund size also reflects the larger financing requirements of companies that have moved beyond their first venture rounds.
International expansion, research and development, regulated product launches, and acquisitions can require significantly more capital once a business reaches growth stage.
Life sciences is particularly exposed to those requirements because clinical development programmes consume money for long periods before products generate commercial revenue.
Software companies generally have fewer physical capital requirements but can use debt to accelerate sales expansion or make acquisitions without reopening their equity structure.
Claret said the latest fund will continue to support international growth, strategic acquisitions, and product innovation.
The manager is also expanding its presence across European technology centres, including additional staff in Paris and planned representation in Berlin.
Local presence can be important in private credit because lending requires detailed assessment of management, shareholder support, cash generation, security, and downside scenarios.
The fundraising also reinforces London’s role as a centre for private-market investment management even where much of the underlying capital is deployed into companies elsewhere in Europe.
UK-based fund managers increasingly operate on a pan-European basis, competing for institutional commitments and growth-company transactions across multiple jurisdictions.
With nearly a third of the latest capital already deployed, Claret begins the fund’s investment period with an established portfolio rather than an entirely undrawn pool.
The remainder will be deployed into a market where founders must balance the cost and repayment obligations of borrowing against the ownership dilution and valuation implications of issuing new equity.
You must be logged in to post a comment.